Use of erythropoietin in heart failure management.

about

Use of erythropoietin in heart failure management.

Item

http://www.wikidata.org/entity/Q35923151

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Use of erythropoietin in heart failure management.

@ast

Use of erythropoietin in heart failure management.

@en

type

Item

label

Use of erythropoietin in heart failure management.

@ast

Use of erythropoietin in heart failure management.

@en

prefLabel

Use of erythropoietin in heart failure management.

@ast

Use of erythropoietin in heart failure management.

@en

P1476

Use of erythropoietin in heart failure management.

@en

P2093

Judy W M Cheng

http://www.w3.org/2001/XMLSchema#string

Krista Caiola

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart.

Erythropoietin and transferrin metabolism in nephrotic syndrome.

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.

Recombinant erythropoietin in clinical practice.

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.

Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study.

The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron.

The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.

Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE).

P304

2145-2149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1E143

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15494385

http://www.w3.org/2001/XMLSchema#string

P921

Erythropoietin